Activated donor immune cells may prevent severe complication after allogeneic stem cell transplantation

Researchers have successfully conducted the first clinical trial using activated regulatory T cells (ATregs, Actileucel)—derived from white blood cells of healthy blood donors. This novel cell therapy aims to prevent graft-versus-host disease (GvHD) following an allogeneic stem cell transplant. The Phase I/II study has yielded extremely encouraging results: ATregs can be produced within 24 hours and injected immediately afterward; administration is safe and well-tolerated by patients—a significant step toward a widely available cell therapy. The research is published in Transplantation and Cellular Therapy.

Salivary cortisol patterns linked to cognitive decline over 11 years

In a study published in the journal JAMA Network Open, an irregular pattern and consistently higher levels of the stress hormone cortisol in saliva were associated with cognitive decline later in life. Black participants specifically had lower overall cortisol levels and less change in their levels during the day than white participants, according to newly published research.

Sharper reasoning skills in teen years tied to lower dementia risk later in life

Could the way we think in our 20s offer clues about our risk of dementia decades later? Large population studies suggest that people who perform better on thinking ability tests in adolescence or young adulthood are less likely to develop dementia later in life. However, cognitive performance in early adulthood is shaped by more than thinking ability alone; it can also reflect education, life experiences and family environment. This makes it difficult to determine whether scores on cognitive tests are a reliable indicator of future dementia risk.